Novo Nordisk A/S research snapshot
NVO AI stock analysis currently sees Novo Nordisk as a high-margin diabetes and obesity-care leader with a large GLP-1 franchise, a rapidly expanding oral Wegovy portfolio, and meaningful pressure from lower realized prices, competition, and patent exposure. At the July 10, 2026 data cutoff, NVO last closed at $48.88 and the mechanically verified market capitalization was about $217.18 billion. This NVO AI stock analysis uses source-backed facts, scenario ranges, and risk controls. It is informational research, not investment advice.
Current price
$48.88
Market cap
$217.18 billion
AI score
71 / 100
Rating
High-quality metabolic-care leader, execution and pricing risk elevated
Trend status
Long-term recovery trend, short-term momentum neutral
Data cutoff (updated weekly)
July 10, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Novo Nordisk converts peptide science, clinical evidence, regulatory approvals, manufacturing, and physician and payer access into recurring revenue in diabetes, obesity, and rare disease care. | High |
| Moat | Patents, clinical evidence, trusted brands, device and peptide know-how, manufacturing scale, and global commercial access reinforce each other, but the moat is tested by rival GLP-1 therapies and exclusivity losses. | Medium-high |
| Management | Mike Doustdar and the leadership team should be judged by pricing discipline, capacity returns, pipeline productivity, integration of acquired assets, and whether capital allocation protects long-term owner earnings. | Medium |
| Financial trend | FY2025 sales grew 6.4% to DKK 309.1 billion and net profit grew 1.4% to DKK 102.4 billion. Q1 2026 reported sales reached DKK 96.8 billion, but adjusted sales fell 4% at CER after excluding a 340B provision reversal. | High |
| Valuation | At $48.88, the audited framework using FY2025 diluted EPS translated at the July 10 quote context indicates about 13.5x earnings and 23.5x FY2025 free cash flow per ADR. These ratios need live currency and earnings updates. | Medium |
| Technical trend | NVO closed near its 50-day moving average, remained above its 100-day and 200-day averages, and had a neutral RSI near 46.2. Moving averages were constructive while shorter-term indicators were mixed. | Medium |
| Risk level | Risk is medium-high because lower realized prices, Lilly and generic competition, reimbursement, patent exposure, pipeline execution, manufacturing costs, and currency can all affect earnings. | Medium-high |
| AI confidence | Reported results and calculation inputs are well documented. Confidence is lower for exact price outcomes because policy, clinical, and competitive events can move pharmaceutical shares sharply. | High data confidence |
| Investment certainty | Medium certainty. NVO has a durable franchise, but a buy decision requires an explicit view on future pricing, market share, patent timing, and the required margin of safety. | Medium |
NVO AI stock forecast
The NVO AI stock forecast uses scenario ranges, not a precise prediction. A three-year model audited with financial_rigor.py used the $48.88 price, an approximately $3.62 FY2025 diluted EPS equivalent, and distinct growth and terminal multiple assumptions. It produces a bearish area near $25 to $27, a base area near $50 to $54, and a bullish area near $80 to $85.
$80 to $85 over three years
More likely if Wegovy pill and HD expand the treated population, volume growth offsets lower prices, obesity market share stabilizes, new indications and pipeline assets deliver, and investors pay a premium multiple near 17x earnings.
$50 to $54 over three years
More likely if earnings grow around low single digits, cost and capacity investments normalize, realized prices remain under pressure but manageable, and the market values NVO near 13x earnings.
$25 to $27 over three years
More likely if price declines outrun volume growth, Eli Lilly or lower-cost alternatives take share, patent losses accelerate, pipeline evidence disappoints, or the earnings multiple contracts toward 9x.
NVO AI technical analysis
NVO AI technical analysis is mixed as of the July 10, 2026 cutoff. StockAnalysis recorded a July 9 close of $48.88. Investing.com showed a neutral overall technical summary, a 14-day RSI of 46.169, a 50-day simple moving average of $49.20, a 100-day average of $47.92, and a 200-day average of $45.73. Technical levels are snapshots and should be confirmed with live chart data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $48.88 | StockAnalysis listed the July 9, 2026 closing price at $48.88. The market was not open at the July 10 research cutoff. |
| Near support | $47.90 to $48.00 | The 100-day simple moving average was $47.92, making this the first support area to monitor. |
| Major support | $45.70 to $46.60 | The 200-day simple and exponential averages were $45.73 and $46.56. A sustained break below this zone would weaken the longer-term recovery signal. |
| Near resistance | $49.20 to $49.50 | The 50-day simple average was $49.20 and the July 8 intraday high was $49.47, creating a nearby confirmation zone. |
| 50-day moving average | $49.20 simple | Price was slightly below the 50-day simple average, so short-term trend confirmation was incomplete. |
| 200-day moving average | $45.73 simple | Price remained above the 200-day simple average, supporting the longer-term trend. |
| Momentum | 14-day RSI 46.169, MACD -0.08 | RSI was neutral and MACD was negative, which argues for confirmation rather than assuming momentum is bullish. |
| Volume | 5.03 million shares on July 9 | Compare future breakouts with recent volume because pharmaceutical news can produce fast, event-driven moves. |
| Volatility | 14-day ATR 0.3032 | The technical snapshot classified recent volatility as lower, but earnings, trials, reimbursement, and regulatory news can invalidate that condition quickly. |
| Invalidation | Close below $47.90, then $45.70 | A break below the 100-day average weakens the setup. A sustained break below the 200-day average calls for a fresh fundamental and technical review. |
NVO AI trading strategy
The NVO AI trading strategy is a rules-based research framework for a pharmaceutical company facing both strong metabolic-care demand and material pricing risk. It is not personalized advice and should be paired with live quotes, position sizing, filings, and an event calendar.
Watch for NVO to reclaim the $49.20 to $49.50 area and hold above the 50-day average with volume confirmation before treating the recovery as a confirmed short-term trend.
A close below $47.90 should weaken the setup. A sustained break below $45.70 should invalidate the longer-term technical thesis until reassessed.
If NVO pulls back toward the 100-day or 200-day average without a new pricing, clinical, or guidance problem, compare the reaction with Wegovy, Ozempic, obesity volume, and realized-price evidence.
Do not average down without a defined loss limit. A technical support level is not a substitute for evidence that the earnings thesis remains intact.
Track adjusted sales growth, realized prices, Wegovy pill adoption, obesity-care market share, GLP-1 diabetes sales, gross margin, capital spending, Q2 results, and regulatory or patent developments.
Reduce confidence if reported growth is driven by non-recurring items, if adjusted sales and operating profit keep declining, or if volume growth cannot offset price and market-share pressure.
Investment research summary
Novo Nordisk earns recurring medicine revenue by pairing peptide innovation, clinical evidence, regulatory approvals, manufacturing, and commercial access for chronic diabetes, obesity, and rare disease care.
The moat rests on trusted brands, clinical data, intellectual property, device and manufacturing expertise, global distribution, and payer relationships. It weakens when competitors offer better outcomes, access, or prices.
The thesis fails if realized prices fall faster than volume rises, competitors take share, patents open markets to lower-cost alternatives, pipeline investments do not extend the franchise, or capital spending fails to earn adequate returns.
Management must balance growth investment with price discipline, capacity returns, clinical productivity, and transparent treatment of non-recurring items. The test is durable owner earnings, not only prescription volume.
Obesity and diabetes care address large chronic-disease needs and can grow for years. The same opportunity attracts large competitors, payer scrutiny, policy attention, and rapid innovation cycles.
The current multiple is lower than the peak-growth period, but it still requires an underwriting view on sustainable earnings after price pressure and competition. Margin of safety depends on execution, not on the size of the GLP-1 market alone.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NVO closing price | $48.88 on July 9, 2026 | StockAnalysis historical prices | July 10, 2026 |
| Market capitalization | $217.18 billion, verified as $48.88 x 4.443 billion shares | financial_rigor.py market-cap verification | July 10, 2026 |
| FY2025 net sales | DKK 309.064 billion, up 6.4% | Novo Nordisk Annual Report 2025 and StockAnalysis cross-check | July 10, 2026 |
| FY2025 net profit | DKK 102.434 billion, up 1.4% | Novo Nordisk Annual Report 2025 and StockAnalysis cross-check | July 10, 2026 |
| FY2025 free cash flow | DKK 28.295 billion | Novo Nordisk Annual Report 2025 and StockAnalysis cross-check | July 10, 2026 |
| FY2025 obesity-care sales | DKK 82.347 billion, up 26% | Novo Nordisk Annual Report 2025 | July 10, 2026 |
| Q1 2026 reported and adjusted sales | DKK 96.823 billion reported, DKK 70.063 billion adjusted | Novo Nordisk Q1 2026 financial report | July 10, 2026 |
| 2026 adjusted sales and operating profit outlook | -4% to -12% at CER after Q1 update | Novo Nordisk Q1 2026 financial report | July 10, 2026 |
| Technical snapshot | RSI 46.169, 50-day SMA $49.20, 200-day SMA $45.73 | Investing.com technical analysis | July 10, 2026 |
This page is an informational research tool, not investment advice or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available data and assumptions. They can be wrong, and readers should verify current information and consider their own objectives and risk tolerance.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
